Mechanism of Action
Bioactive Fragment Generation
Chromogranin A undergoes tissue-specific proteolytic processing to generate distinct bioactive peptides: vasostatin-1 (CgA1-76, inhibits vasoconstriction and cardiostimulation), pancreastatin (CgA250-301, inhibits insulin secretion and promotes insulin resistance), catestatin (CgA352-372, inhibits catecholamine secretion from chromaffin cells), and chromostatin (CgA176-195, inhibits chromaffin exocytosis). These fragments often have opposing effects to the original secretagogue.
Catestatin Mechanism
Catestatin, the most studied CgA-derived peptide, is a nicotinic acetylcholine receptor antagonist that acts in an autocrine/paracrine loop to inhibit further catecholamine release from adrenal chromaffin cells and sympathetic nerve terminals. Catestatin also acts on mast cells to promote histamine release and has antimicrobial properties at higher concentrations.
Research Summary
Neuroendocrine Tumor Biomarker
ClinicalSerum chromogranin A is elevated in over 80% of NETs regardless of tumor secretory status, making it the most sensitive general NET marker. CgA levels correlate with tumor burden and treatment response. Serial CgA measurements guide treatment decisions in carcinoid tumors, pancreatic NETs, and pheochromocytomas. Limitations include false elevations with proton pump inhibitor use.
Cardiovascular Role
PreclinicalCgA-null mice show hypertension and cardiac hypertrophy, establishing CgA and its fragments as endogenous modulators of cardiovascular function. Vasostatin inhibits endothelin-1-induced vasoconstriction, while catestatin has vasodilatory effects and may regulate sympathetic tone. Plasma CgA is elevated in heart failure and correlates with BNP levels.
Calculate your Chromogranin A dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| NET diagnosis | Serum CgA measurement | Clinical assay | Blood draw |
| Treatment monitoring | Serial serum CgA | Every 3-6 months | Blood draw |
CgA is a diagnostic biomarker, not a therapeutic. Avoid PPIs before testing (cause false elevation).
Interactions
Safety Profile
Chromogranin A is an endogenous protein with physiological roles in neuroendocrine secretion. No therapeutic exogenous use. CgA-derived peptides (catestatin, vasostatin) are being explored therapeutically. Elevated serum CgA in NETs reflects tumor burden and warrants imaging evaluation.
References
- [1]Taupenot L et al. (2003). The chromogranin-secretogranin family. New England Journal of Medicine, 348(12), 1134-1149.
- [2]Hsiao RJ et al. (1991). Human chromogranin A: measurement by a specific radioimmunoassay in normal subjects and in patients with endocrine tumors. Journal of Clinical Endocrinology and Metabolism, 73(4), 820-827.